Abstract | BACKGROUND: PATIENTS AND METHODS: Twelve patients were enrolled in this ongoing trial with a projected number of 30 patients and received 5 cycles of weekly Taxol (40 mg/m2) and carboplatin (AUC 1.5) with conventional radiotherapy (40 Gy). Within 3 to 4 weeks after chemoradiotherapy resection of the primary tumor and the regional neck nodes was performed. RESULTS: So far 12 patients were evaluable for toxicity and response. Complete response was noted in 8/12 patients (CR 66%). In 6/10 patients (60%) complete pathologic response was documented in the resection specimens. CONCLUSION:
|
Authors | A Eckardt, I Wildfang, J H Karstens |
Journal | Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
(Strahlenther Onkol)
Vol. 175 Suppl 3
Pg. 11-3
(Oct 1999)
ISSN: 0179-7158 [Print] Germany |
Vernacular Title | Simultane Radiochemotherapie mit Taxol/Carboplatin bei fortgeschrittenen operablen Kopf-Hals-Tumoren. Vorläufige Ergebnisse. |
PMID | 10554639
(Publication Type: Clinical Trial, Clinical Trial, Phase II, English Abstract, Journal Article)
|
Chemical References |
- Radiation-Sensitizing Agents
- Carboplatin
- Paclitaxel
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carboplatin
(administration & dosage, adverse effects)
- Carcinoma, Squamous Cell
(drug therapy, pathology, radiotherapy, surgery)
- Combined Modality Therapy
- Female
- Humans
- Male
- Middle Aged
- Mouth Neoplasms
(drug therapy, pathology, radiotherapy, surgery)
- Neoadjuvant Therapy
- Neoplasm Staging
- Paclitaxel
(administration & dosage, adverse effects)
- Radiation-Sensitizing Agents
(administration & dosage, adverse effects)
- Radiotherapy Dosage
- Treatment Outcome
|